BioMedNewsBreaks

MondayOct 26, 2020 11:49 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Featured in Seeking Alpha Article Discussing Its Disruption in Chronic Disease Market

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, was featured in a recent Seeking Alpha news article. The piece, titled “DarioHealth: Don't Overlook This Mini Livongo,” discusses disruptors in the chronic disease market, such as Omada Health, Virta Health and Lark Health. The article specifically focuses on DRIO and the competition it brings to larger players like Livongo Health Inc. (NASDAQ: LVGO), which generated great returns for investors. The article reads, “After LVGO got bought out, I started to look for other digital health plays, specifically competitors to LVGO. Recently, I found a tiny company called DarioHealth (NASDAQ:…

Continue Reading

FridayOct 23, 2020 12:06 pm

BioMedNewsBreaks – KBL Merger Corp. IV’s (NASDAQ: KBLM) Special Meeting to be Held November 5, 2020, 180 Life Sciences Featured in Exclusive Broadcast

KBL Merger Corp. (NASDAQ, KBLMKBL, KBLMR, KBLMW) (“KBL”), a special purpose acquisition company (“SPAC”) that previously announced the agreement to acquire 180 Life Sciences Corp., today announced postponement of the special meeting of its stockholders (the “Special Meeting”) to November 5, 2020. KBL determined to postpone the Special Meeting (originally scheduled for Monday, October 26, 2020) so that it better aligns with anticipated timing of the proposed business combination with 180 Life Sciences. As a result of this change, the Special Meeting will now be held at 10:00 a.m., local time, on November 5, 2020, at the offices of KBL…

Continue Reading

WednesdayOct 21, 2020 11:47 am

BioMedNewsBreaks – 180 Life Sciences Corp. Featured in NNW Editorial Discussing Big Pharma Acquisitions

180 Life Sciences Corp. was discussed prominently in an editorial published by NetworkNewsWire (“NNW”), one of 50-plus brands in the InvestorBrandNetwork (“IBN”). The editorial, titled “Banking on the Next Blockbuster Drug,” discusses the significant amounts of time and money being invested by big pharma companies in the pursuit of new drugs, especially those that offer the potential to become blockbuster drugs. A blockbuster drug, or one that generates more than $1 billion in annual sales, can provide enormous benefits for the company that owns and manufactures it. Therefore, large companies operating in the pharmaceutical space commonly acquire promising new drugs — and…

Continue Reading

WednesdayOct 21, 2020 10:53 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Forms New Scientific Advisory Board

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins, has announced  the formation of a Scientific Advisory Board (“SAB”) designed to provide the company with invaluable expertise and insights. The company also announced that three leading global experts in exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis have been appointed to the board: Michael Konstan, MD; Darwin L. Conwell, MD; and Michael Wilschanski, MD. Konstan is vice dean for translational research and the Gertrude Lee Chandler Tucker Professor of Pediatrics at Case Western Reserve University School of Medicine; he…

Continue Reading

TuesdayOct 20, 2020 10:06 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Completion of Manufacturing of Lead Drug Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has completed the manufacturing process for Berubicin Drug Product. CNSP’s U.S. manufacturer, Pharmaceutics International Inc. ("Pii"), has finished manufacturing the drug, which is the company’s lead drug candidate for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of incurable brain cancer. In an attempt to diversify its supply chain, provide for local accessibility of Berubicin and reduce COVID-19-related delay risks, CNS had implemented a dual-track drug product manufacturing approach that used two different manufacturers for…

Continue Reading

MondayOct 19, 2020 12:21 pm

BioMedNewsBreaks – Why CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Is ‘One to Watch’

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. A recent article discussing CNS Pharmaceuticals reads, “The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1…

Continue Reading

FridayOct 16, 2020 12:45 pm

BioMedNewsBreaks – KBL Merger Corp. IV (NASDAQ: KBLM) Featured in Seeking Alpha Article Discussing ‘Blockbuster Year for SPACs’

KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that previously announced the acquisition of 180 Life Sciences, was featured in a Seeking Alpha news article. The piece discussed a “blockbuster year for SPACs,” indicating that, to date, fiscal year 2020 has seen 127 SPAC IPOs collectively raise over $48.5 billion in proceeds. This represents significantly more than the previous ten years combined. The article covers the process of going public via a SPAC as a cost-effective way to complete a M&A deal in weeks instead…

Continue Reading

ThursdayOct 15, 2020 1:58 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Looks to Bright Future with First Contract on the Books

Predictive Oncology (NASDAQ: POAI)’s Soluble Biotech division has finalized its first substantial contract with a pharmaceutical company since its acquisition by POAI earlier this year (https://ibn.fm/gXjd2). Soluble Biotech is a provider of stable and soluble formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. Under the contract, Soluble Biotech will provide its expertise in protein expression and solubility studies. A recent article discussing this quotes Soluble Biotech founder Dr. Larry DeLucas. “Our first contract is a major milestone and validates our recent move into a new, larger facility,” Dr. DeLucas stated. “We quadrupled our laboratory and…

Continue Reading

WednesdayOct 14, 2020 11:00 am

BioMedNewsBreaks – Oncocyte Corporation (NYSE American: OCX) Presents New DetermaRx(TM) Prospective Data at IASLC 2020 Conference

Oncocyte (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, is presenting new prospective data on DetermaRx(TM) at the IASLC 2020 North America Conference on Lung Cancer taking place on October 22. Gavitt Woodard, M.D., assistant professor, Yale School of Medicine, and lead author on the study is presenting the data at the event hosted by the International Association for the Study of Lung Cancer. Per the update, DetermaRx is a treatment stratification test that identifies stage I-IIA non-small cell lung cancer (“NSCLC”) patients at high-risk…

Continue Reading

WednesdayOct 14, 2020 10:44 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Adds More Sites for Cystic Fibrosis Clinical Trials

AzurRx BioPharma (NASDAQ: AZRX) has activated additional clinical trial sites for its trial of MS1819 in cystic fibrosis. The company specializes in the development of nonsystemic, recombinant therapies for gastrointestinal diseases. The company has activated two additional trial sites in Turkey for its Phase 2 combination therapy trial of its lead drug candidate, MS1819. MS1819 is a recombinant lipase for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients suffering from chronic pancreatitis and cystic fibrosis. Patient screening has already been initiated for the new trial sites, with topline data expected by Q2 2021. AzurRx had previously activated six clinical sites in Hungary,…

Continue Reading